River Blindness or onchocerciasis is caused by the prelarval (microfilaria) and adult stages of the filarial nematode Onchocerca volvulus. The disease is transmitted by the bite of certain species of female Simulium flies (black flies) that bite by day and are found near rapidly flowing rivers and streams. Onchocerciasis is endemic in more than 25 nations located in a broad band across the central part of Africa. Small endemic foci are also present in the Arabian Peninsula (Yemen) and in the Americas (Brazil, Colombia, Ecuador, Guatemala, southern Mexico, and Venezuela)
Researchers at the LSTM's Centre for Drugs and Diagnostics, and University of Buea, Cameroon have developed new models of the tropical eye worm, Loa loa for the development of new drugs against filariasis.
The microorganisms that cause malaria, leishmaniasis and a variety of other illnesses today can be traced back at least to the time of dinosaurs, a study of amber-preserved blood-sucking insects and ticks show.
TGen North, the Pathogen and Microbiome Division of the Translational Genomics Research Institute, has partnered with the non-profit NARBHA Institute to advance human health through the new TGen One Health Collaborative, an initiative that recognizes the interdependence of people, animals and plants in both the human-built and natural environments.
Scientists at Scripps Research have developed a urine diagnostic to detect the parasitic worms that cause river blindness, also called onchocerciasis, a tropical disease that afflicts 18 to 120 million people worldwide.
River blindness and elephantiasis are debilitating diseases caused by parasitic worms that infect as many as 150 million people worldwide.
The Berkeley researchers figured out that they could quickly determine who has the Loa loa worm using a smartphone, customized to work like a microscope. They could then skip the medication for those people and give it to everyone else. Kamgno, who received the latest version of the phones in 2016, dubbed the mobile microscopes "revolutionary."
River blindness, or onchocerciasis, is a disease caused by a parasitic worm found primarily in Africa. The worm (Onchocerca volvulus) is transmitted to humans as immature larvae through bites of infected black flies.
Researchers from LSTM's Research Centre for Drugs and Diagnostics have found a way of significantly reducing the treatment required for lymphatic filariasis and onchocerciasis from several weeks to seven days. By targeting Wolbachia, a bacterial symbiont that the filarial parasites need to live, the team has discovered a drug synergy that enables effective treatment over a shorter time.
In a small, randomized Phase I/II clinical trial (SAT1), researchers at University of California San Diego School of Medicine say a 100-year-old drug called suramin, originally developed to treat African sleeping sickness, was safely administered to children with autism spectrum disorder (ASD), who subsequently displayed measurable, but transient, improvement in core symptoms of autism.
Since 2007, the World Health Organization (WHO) has been reporting outstanding success in dealing with neglected tropical diseases (NTDs) with 1 billion people estimated to have received treatments in 2015.
Research teams from the National Institutes of Health and abroad have identified the first inhibitor of an enzyme long thought to be a potential drug target for fighting disease-causing parasites and bacteria.
SUGAR-based adjuvants from Australia are boosting the effectiveness of vaccines to target some of the world’s deadliest diseases.
The parasite that causes river blindness infects about 37 million people in parts of Africa and Latin America, causing blindness and other major eye and skin diseases in about 5 million of them.
Scientists have sequenced the genome of the parasitic worm responsible for causing onchocerciasis--an eye and skin infection more commonly known as river blindness.
Geographers at the University of Southampton have completed a large scale data and mapping project to track the flow of internal human migration in low and middle income countries.
PATH and Standard Diagnostics/Alere announced today the commercial availability of two rapid diagnostic tools for onchocerciasis and lymphatic filariasis. Designed for use in disease surveillance, the antibody-based tests are part of a suite of diagnostic innovations intended to support the elimination of neglected tropical diseases (NTDs), a group of illnesses that affect more than a billion people worldwide.
The acclaimed public television documentary series Global Health Frontiers expands to a weekly newsmagazine with four one-hour episodes combining compelling journalism from the leading edges of global health developments with a fast-paced and energetic style.
Many of the drugs we use in hospitals – antibiotics, antifungals and anti-cancer drugs, to name but a few – are produced by bacteria that live in the soil beneath our feet.
The world's first vaccine for a disease that causes misery for millions in Africa could be tested within five years.
Researchers at Washington University School of Medicine in St. Louis have received a $7 million grant from the Bill & Melinda Gates Foundation aimed at eliminating river blindness and elephantiasis, two neglected tropical diseases that annually sicken millions.